journal article·2018-02-17Open access

Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line

Hajar Shali, Mahdi Shabani, Fatemeh Pourgholi, Mahsa Hajivalili, Leili Aghebati-Maleki, Farhad Jadidi-Niaragh, Behzad Baradaran, Ali Akbar Movassaghpour Akbari, Vahid Younesi, Mehdi Yousefi

Abstract

Here, we investigated the effects of dual delivery of IGF-1R siRNA and doxorubicin by chitosan nanoparticles on viability of A549 lung cancer cells line by utilization of MTT and qRT-PCR. Furthermore apoptosis and migration of treated cells were assessed by Annexin-PI and wound healing assays, respectively. The chitosan nanoparticles had about 176 nm size with zeta potential and polydispersive index about 11 mV and 0.3, respectively. The IGF-1R siRNA had synergistic effect on DOX-induced cytotoxicity and apoptosis in tumour cells. In addition, siRNA/DOX-loaded chitosan nanoparticles could significantly decrease migration and expressions of mmp9, VEGF and STAT3 in A549 cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences

Student’s Research Committee, Tabriz University of Medical Sciences

Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences

Department of Immunology, Tabriz University of Medical Sciences

Hematology and Oncology Research Center, Tabriz University of Medical Sciences

Pishtaz Teb Diagnostics

Faculty of Paramedical Sciences, Alborz University of Medical Sciences

Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences

Department of Immunology, School of Medicine, Tabriz University of Medical Sciences

Funding

Tabriz University of Medical Sciences

References (41)

Show source-provided references
1. 10.1038/nrclinonc.2011.8210.1038/nrclinonc.2011.82 ↗
2. 10.1002/cncr.2476010.1002/cncr.24760 ↗
3. 10.1016/S1470-2045(09)70364-X10.1016/S1470-2045(09)70364-X ↗
4. 10.1111/j.1440-1843.2007.01105.x10.1111/j.1440-1843.2007.01105.x ↗
5. Rami-Porta R, Crowley JJ, Goldstraw P. Review the revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15:5.
6. Fathi Karkan S, Mohammadhosseini M, Panahi Y, et al. Magnetic nanoparticles in cancer diagnosis and treatment: a review. Artif Cells, Nanomed Biotechnol. 2016.
7. 10.1056/NEJMoa01195410.1056/NEJMoa011954 ↗
8. 10.1016/j.biomaterials.2010.12.06110.1016/j.biomaterials.2010.12.061 ↗
9. 10.3816/CLC.2009.n.03810.3816/CLC.2009.n.038 ↗
10. 10.1155/2012/96734710.1155/2012/967347 ↗
11. 10.1038/nrc90310.1038/nrc903 ↗
12. 10.3109/21691401.2014.97523710.3109/21691401.2014.975237 ↗
13. 10.1155/2013/86395110.1155/2013/863951 ↗
14. 10.1016/j.jconrel.2006.08.01310.1016/j.jconrel.2006.08.013 ↗
15. 10.3109/21691401.2014.99883010.3109/21691401.2014.998830 ↗
16. 10.1016/j.colsurfb.2009.09.00110.1016/j.colsurfb.2009.09.001 ↗
17. 10.1111/jphp.1259310.1111/jphp.12593 ↗
18. 10.1080/0265204080197046110.1080/02652040801970461 ↗
19. 10.1080/21691401.2016.126057810.1080/21691401.2016.1260578 ↗
20. 10.1248/cpb.59.31510.1248/cpb.59.315 ↗
21. 10.1016/j.gendis.2014.10.00410.1016/j.gendis.2014.10.004 ↗
22. 10.1016/j.biopha.2016.05.03410.1016/j.biopha.2016.05.034 ↗
23. 10.1016/j.ctrv.2011.07.00810.1016/j.ctrv.2011.07.008 ↗
24. 10.1177/175883401142757610.1177/1758834011427576 ↗
25. 10.1002/mc.2234210.1002/mc.22342 ↗
26. 10.1111/j.1745-7270.2007.00257.x10.1111/j.1745-7270.2007.00257.x ↗
27. 10.1007/s13277-015-4732-010.1007/s13277-015-4732-0 ↗
28. 10.1055/s-2004-81414310.1055/s-2004-814143 ↗
29. 10.2174/15748921279835793010.2174/157489212798357930 ↗
30. 10.1677/erc.1.0128010.1677/erc.1.01280 ↗
31. 10.1136/esmoopen-2016-00006010.1136/esmoopen-2016-000060 ↗
32. 10.1593/neo.0931010.1593/neo.09310 ↗
33. 10.1002/ijc.2054310.1002/ijc.20543 ↗
34. 10.1016/j.canlet.2004.10.00210.1016/j.canlet.2004.10.002 ↗
35. 10.1016/j.febslet.2005.08.00410.1016/j.febslet.2005.08.004 ↗
36. 10.1038/nbt0502-49710.1038/nbt0502-497 ↗
37. 10.1016/j.bbrc.2011.06.01910.1016/j.bbrc.2011.06.019 ↗
38. Yin M, Guan X, Liao Z, et al. Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res. 2009;1:101–114.
39. 10.3892/ol.2013.137510.3892/ol.2013.1375 ↗
40. 10.1016/j.bcp.2010.05.01110.1016/j.bcp.2010.05.011 ↗
41. 10.1128/MCB.26.2.413-424.200610.1128/MCB.26.2.413-424.2006 ↗